Benefits of deep-vein thrombosis prophylaxis in the nonsurgical patient: The MEDENOX trial☆
References (36)
- et al.
Prevention of venous thromboembolism
Chest
(1998) - et al.
Prevention of venous thromboembolism
Chest
(1995) - et al.
Utilization of venous thromboembolism prophylaxis in the medical intensive care unit
Chest
(1994) - et al.
Venous thromboembolism prophylaxis, or lack of …
Chest
(1995) - et al.
The effect of dicoumarol upon the mortality and incidence of thromboembolic complication of congestive heart failure
Am Heart J
(1950) Venous thromboembolic disease management of the non-surgical moderate- and high-risk patient
- et al.
Autopsyverified pulmonary embolism in a surgical department: Analysis of the period from: 1951 to 1988
Br J Surg
(1951) - et al.
Incidence of venous thromboembolism verified by necropsy over 30 years
BMJ
(1991) - et al.
The prevalence of risk factors for venous thromboembolism among hospital patients
Arch Intern Med
(1992) - et al.
A prospective study of the incidence of deep-vein thrombosis within a defined urban population
J Intern Med
(1992)
International Consensus Statement: Prevention of venous thromboembolism. International Consensus Statement (guidelines according to scientific evidence)
Int Angiol
Cost-benefit analysis of prophylaxis against deep vein thrombosis in surgery
Risk of and prophylaxis for venous thromboembolism in hospital patients
Phlebology
Autopsy proven pulmonary embolism in hospital patients: Are we detecting enough deep vein thrombosis?
J R Soc Med
The changing pattern of venous thromboembolic disease
Haemostasis
Physician practices in the prevention of venous thromboembolism
Ann Intern Med
Risk of and prophylaxis for venous thromboembolism in hospital patients
BMJ
Prevention of deep vein thrombosis in medical patients by lowdose heparin
Scott Med J
Cited by (21)
Thromboembolism in lung cancer - An area of urgent unmet need
2014, Lung CancerCitation Excerpt :It is a potent negative predictor of survival and a leading cause of death [1,6]. Appropriate pharmacological thromboprophylaxis (P-TP) can be a highly cost-effective preventative strategy with the potential to reduce the incidence of TE in high-risk patients by up to 80% [7–9]. While all patients with cancer should be considered at risk of TE, the risk is dynamic, and the absolute magnitude and duration of TE risk is not equal for all patients or for a given individual over time.
Haemostatic challenges in the cancer patient: Focus on the perioperative period
2013, Best Practice and Research: Clinical AnaesthesiologyCitation Excerpt :Registry and retrospective studies have demonstrated that postoperative TE results in excess length of hospital stay, excess mortality and health costs [36]. Importantly, TE is preventable with appropriate utilisation of P-TP in up to 80% of high-risk patients, with substantial clinical evidence from randomised controlled trials (RCTs) and meta-analyses supporting its safety and cost-effectiveness [37–42]. Economic evaluation of hospitalised and surgical cancer patients has shown cost benefit with the administration of P-TP, largely due to the increased morbidity (and mortality) and requirement for increase health resource utilisation associated with TE.
Venous thromboembolism in acutely ill hospitalized medical patients
2010, Thrombosis ResearchCitation Excerpt :The implementation of thromboprophylaxis strategies provides benefit to patients, and should also help protect their caregivers and hospitals for legal liability [2]. Unfortunately, despite the number of randomized trials demonstrating the benefit of thromboprophylaxis [3–6], low adherence is frequent, and the number of patient with VTE is higher than expected, [7–9] specially in medical populations [3]. A number of reasons may account for this situation: the apparent greater heterogeneity of medical patients compared with surgical patient may limit accurate assessment of the overall burden of VTE in medical patients; identifying individual medical patient at high risk for VTE may seem difficult.
Treatment and prevention of thrombosis during treatment of lung cancer
2009, Revue des Maladies Respiratoires ActualitesVenous thromboembolism and cancer
2008, Revue de Pneumologie CliniqueAppropriateness of thromboprophylaxis in medical and surgical inpatients
2007, Revista de Calidad Asistencial
- ☆
Based on a presentation delivered at a satellite symposium to the 1999 meeting of the International Society on Thrombosis and Haemostasis.